Imagenebio Inc (IMA)

Mar 11, 2026

ImageneBio, Inc. 2025 10-K: IMG-007 Clinical Development, Strategy, and Market Opportunities in Immunological Diseases - Minichart

Mar 11, 2026

Mar 11, 2026

Legal and Regulatory Risks: How Litigation and Government Actions Could Impact Imagenebio, Inc.’s Financial Performance - TipRanks

Mar 11, 2026

Mar 10, 2026

ImageneBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 10, 2026

Mar 10, 2026

ImageneBio 10-K: License revenue $0.8M; Net loss $45.3M - TradingView

Mar 10, 2026

Mar 10, 2026

ImageneBio (NASDAQ: IMA) bets on OX40 antibody IMG-007 after Ikena merger - Stock Titan

Mar 10, 2026

Mar 10, 2026

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update - The Manila Times

Mar 10, 2026

Mar 07, 2026

Blue Owl Capital Holdings LP Purchases New Stake in ImageneBio, Inc. $IMA - MarketBeat

Mar 07, 2026

Mar 02, 2026

ImageneBio Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView

Mar 02, 2026

Mar 02, 2026

IMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 02, 2026

Feb 27, 2026

IMA,CVRX Revenue Breakdown - Finviz

Feb 27, 2026

Feb 26, 2026

ImageneBio to Participate in Leerink Global Healthcare Conference - Eagle-Tribune

Feb 26, 2026

Feb 23, 2026

BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA - Defense World

Feb 23, 2026

Feb 20, 2026

ImageneBio (NASDAQ:IMA) Shares Up 2.4% – Still a Buy? - Defense World

Feb 20, 2026

Feb 17, 2026

ImageneBio announces immediate resignation of board director - TipRanks

Feb 17, 2026

Feb 17, 2026

ImageneBio (NASDAQ: IMA) prospectus supplement updates resale of 2.5M shares - Stock Titan

Feb 17, 2026

Feb 17, 2026

ImageneBio, Inc. Announces Resignation of Steven Hui Wang as Member of the Board of Directors, Effective on February 12, 2026 - marketscreener.com

Feb 17, 2026

Feb 16, 2026

ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer By Investing.com - Investing.com Nigeria

Feb 16, 2026

Feb 11, 2026

ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer - Investing.com South Africa

Feb 11, 2026

Feb 10, 2026

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - marketscreener.com

Feb 10, 2026

Feb 10, 2026

New ImageneBio CMO to lead late-stage eczema trial using OX40 drug - Stock Titan

Feb 10, 2026

Feb 07, 2026

ImageneBio Debuts on Nasdaq Following Merger Completion - AD HOC NEWS

Feb 07, 2026

Jan 29, 2026

ImageneBio (NASDAQ:IMA) Trading Up 0.5%Should You Buy? - MarketBeat

Jan 29, 2026

Jan 07, 2026

ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Jan 07, 2026

Dec 31, 2025

Joseph Slattery Spends US$96k On ImageneBio Stock - simplywall.st

Dec 31, 2025

Dec 31, 2025

ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap - Yahoo Finance

Dec 31, 2025

Dec 29, 2025

Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks

Dec 29, 2025

Dec 29, 2025

Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock - MarketBeat

Dec 29, 2025

Dec 21, 2025

ImageneBio chief medical officer resigns, transition planned - MSN

Dec 21, 2025

Dec 18, 2025

ImageneBio Chief Medical Officer Resigns, Transition Planned - TipRanks

Dec 18, 2025

Dec 18, 2025

ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025 - marketscreener.com

Dec 18, 2025

Dec 14, 2025

ImageneBio assumed at Underperform from Neutral at Wedbush - MSN

Dec 14, 2025

Dec 13, 2025

ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Dec 13, 2025

Dec 13, 2025

ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of “Hold” by Brokerages - Defense World

Dec 13, 2025

Dec 12, 2025

ImageneBio Extends Agreement with Miragene Inc. - MSN

Dec 12, 2025

Dec 08, 2025

ImageneBio (IMA) price target decreased by 94.20% to 16.32 - MSN

Dec 08, 2025

Dec 02, 2025

ImageneBio (IMA) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 01, 2025

ImageneBio, Inc. (IMA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Dec 01, 2025

Nov 28, 2025

ImageneBio, Inc. (IMA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Nov 28, 2025

Nov 28, 2025

Wedbush Comments on ImageneBio's Q4 Earnings (NASDAQ:IMA) - MarketBeat

Nov 28, 2025

Nov 27, 2025

ImageneBio (NASDAQ:IMA) Lowered to “Underperform” Rating by Wedbush - Defense World

Nov 27, 2025

Nov 27, 2025

ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush - Defense World

Nov 27, 2025

Nov 27, 2025

IMA interactive stock chart | ImageneBio, Inc. stock - Yahoo Finance Australia

Nov 27, 2025

Nov 27, 2025

Price performance - Yahoo Finance Australia

Nov 27, 2025

Nov 27, 2025

ImageneBio (NASDAQ:IMA) Downgraded to Underperform Rating by Wedbush - Defense World

Nov 27, 2025

Nov 27, 2025

ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush - Defense World

Nov 27, 2025

Nov 26, 2025

Sell Recommendation for ImageneBio Due to Strategic Risks and Financial Challenges - TipRanks

Nov 26, 2025

Nov 25, 2025

Wedbush assumes coverage of ImageneBio stock with Underperform rating By Investing.com - Investing.com South Africa

Nov 25, 2025

Nov 25, 2025

ImageneBio (IMA) Receives Underperform Rating from Wedbush | IMA Stock News - GuruFocus

Nov 25, 2025

Nov 25, 2025

Wedbush assumes coverage of ImageneBio stock with Underperform rating - Investing.com India

Nov 25, 2025

Nov 25, 2025

Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target - marketscreener.com

Nov 25, 2025

Nov 22, 2025

ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year - MSN

Nov 22, 2025

Nov 19, 2025

ImageneBio Highlights IMG-007 in Corporate Update - TipRanks

Nov 19, 2025